TY - JOUR
T1 - 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
AU - Calbert, Marissa L
AU - Chandramouly, Gurushankar
AU - Adams, Clare M
AU - Saez-Ayala, Magali
AU - Kent, Tatiana
AU - Tyagi, Mrityunjay
AU - Ayyadevara, V S S Abhinav
AU - Wang, Yifan
AU - Krais, John J.
AU - Gordon, John
AU - Atkins, Jessica
AU - Toma, Monika M
AU - Betzi, Stéphane
AU - Boghossian, Andrew S
AU - Rees, Matthew G
AU - Ronan, Melissa M
AU - Roth, Jennifer A
AU - Goldman, Aaron R
AU - Gorman, Nicole
AU - Mitra, Ramkrishna
AU - Childers, Wayne E
AU - Graña, Xavier
AU - Skorski, Tomasz
AU - Johnson, Neil
AU - Hurtz, Christian
AU - Morelli, Xavier
AU - Eischen, Christine M
AU - Pomerantz, Richard T
N1 - ©2023 American Association for Cancer Research.
PY - 2024/5/2
Y1 - 2024/5/2
N2 - Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4'-ethynyl-2'-deoxycytidine (EdC) as a third-generation anticancer nucleoside prodrug with preferential activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (DCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator. A 2.1Å cocrystal structure of DCK bound to EdC and UDP reveals how the rigid 4'-alkyne of EdC fits within the active site of DCK. Remarkably, EdC was resistant to cytidine deamination and SAMHD1 metabolism mechanisms and exhibited higher potency against ALL compared with FDA-approved nelarabine. Finally, EdC was highly effective against DLBCL tumors and B-ALL in vivo. These data characterize EdC as a preclinical nucleoside prodrug candidate for DLBCL and ALL.
AB - Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4'-ethynyl-2'-deoxycytidine (EdC) as a third-generation anticancer nucleoside prodrug with preferential activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (DCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator. A 2.1Å cocrystal structure of DCK bound to EdC and UDP reveals how the rigid 4'-alkyne of EdC fits within the active site of DCK. Remarkably, EdC was resistant to cytidine deamination and SAMHD1 metabolism mechanisms and exhibited higher potency against ALL compared with FDA-approved nelarabine. Finally, EdC was highly effective against DLBCL tumors and B-ALL in vivo. These data characterize EdC as a preclinical nucleoside prodrug candidate for DLBCL and ALL.
KW - Animals
KW - Cell Line, Tumor
KW - Deoxycytidine Kinase/metabolism
KW - Deoxycytidine/analogs & derivatives
KW - Humans
KW - Leukemia/drug therapy
KW - Lymphoma/drug therapy
KW - Mice
KW - Xenograft Model Antitumor Assays
UR - https://pubmed.ncbi.nlm.nih.gov/38064712/
UR - https://www.scopus.com/pages/publications/85192112868
U2 - 10.1158/1535-7163.MCT-23-0487
DO - 10.1158/1535-7163.MCT-23-0487
M3 - Article
C2 - 38064712
SN - 1535-7163
VL - 23
SP - 683
EP - 699
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 5
ER -